Dr. Rakesh Singal, MD

Dr. Singal practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Singal's NPI, 1245295351, was assigned on April 20, 2006. Dr. Singal graduated from Maulana Azad Medical College in 1984. Dr. Singal holds Florida license ME86476.

Dr. Singal's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Singal's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Singal is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Singal to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Singal practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Singal's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Singal is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Singal's licenses on file in 3 states: Florida, Louisiana and Minnesota.

Dmand AI lists colorectal cancer, deep vein thrombosis (DVT), lung cancer and prostate cancer among the conditions Dr. Singal treats.

CMS data shows 1,749 Medicare services from Dr. Singal across 7 procedure codes in 2024, for 261 Medicare patients. Medicare paid $85,765 for them.

CMS counts 261 Medicare patients who saw Dr. Singal in 2024. The largest group is 75 to 84, with 120 patients. 75% of them have cancer, and 75% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Singal's median patient age at 75, with 12% women.

In 2024, Dr. Singal wrote 66 Medicare Part D claims for 26 patients. 82% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $119 in total drug cost. In 2023, CMS named 27 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Singal for performance year 2024, reported as part of a group. Dr. Singal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Singal as offering telehealth.

Dmand AI links 51 papers to Dr. Singal, published from 2001 to 2023. 2011 was the busiest year, with 3. The most frequent topics are DNA Methylation, Promoter Regions, Genetic and Prostatic Neoplasms. Dr. Singal has published most often in Anticancer Res. Dr. Singal's most frequent co-authors are Murugesan Manoharan, MD, Mark S. Soloway, MD and Ahmed H. Eldefrawy, MD.

Dmand AI links Dr. Singal to 6 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Neoplasm Metastasis. University of Miami sponsors the most, 4. Open Payments lists research payments to Dr. Singal that name 1 trial.

CMS Open Payments shows 22 general payments to Dr. Singal from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Exelixis Inc. paid the most, $3,347. It also lists 1 research payment totaling $365 in 2016, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Singal, most recently CMS Stage 1 EHR in 2013.

Dr. Singal graduated from Maulana Azad Medical College in 1984.

Dr. Singal is in network with 11 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.